Navigation Links
Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
Date:5/30/2008

ine patients met the key inclusion criteria. In patients who received a median of four cycles of eribulin mesylate, Overall Response Rate (ORR) by Independent Review (IR) was 9.3% (all Partial Responses (PR); 95% confidence interval [CI]: 6.1%-13.4%). Investigator-assessed ORR was 14.1% (1 CR; 95% CI: 10.2%-18.9%). Nearly half (46.5%) the patients had stable disease (SD) after treatment with eribulin mesylate. The clinical benefit rate (CBR, defined as CR+PR+SD 6 months) was 17.1% (95% CI: 12.8%-22.1%).

The median duration of response was 4.2 months (126 days, range: 42 -258 days; 95% CI: 86-147). Median progression-free survival (PFS) was 2.6 months (79 days, range: 1*-397 days), and the median overall survival (OS) rate was 10.3 months (315 days, range: 19-604 days; 95% CI: 279-350). The six-month PFS and OS rates were 16.0% (95% CI: 8.6-17.0) and 72.3%, respectively (95% CI: 66.9-77.6).

The safety analysis included all 291 patients who received treatment with eribulin mesylate. Patients with up to Grade 2 peripheral neuropathy were included in the study. The most frequently reported Grade 3 (severe) or Grade 4 (disabling or life- threatening) adverse events were neutropenia (a decrease in the number of granular white blood cells, 54%); febrile neutropenia, 5.5%, leukopenia (low white blood cell count, 14%), and weakness/fatigue (10%; no Grade 4 events). Grade 3 peripheral neuropathy (a functional disturbance or damage to nerves outside the brain and spinal cord) was reported in 5.5% of patients. No Grade 4 peripheral neuropathy events were reported. No correlation was seen between Grade 2 peripheral neuropathy and deterioration.

"In this study, eribulin mesylate appeared to have an acceptable tolerability profile, particularly with regard to the low incidence of peripheral neuropathy," noted Vahdat. "None of the reported cases of neuropathy were disabling, suggesting that eribulin mesylate, if approved, may be a useful addit
'/>"/>

Contact: Judee Shuler
201-746-2241
Eisai Inc.
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. UM coral scientist Peter Glynn wins award for scholarly activity
2. Blood pressure drug telmisartan shows powerful activity against stroke
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
5. Cell-based therapy shows promise in patients with Parkinsons disease
6. Scientists test device to track medication adherence in patients with HIV/AIDS
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
9. Pregnant patients lose out in breast cancer treatment; a new approach is needed
10. Mental stress reduces blood flow to the heart in patients with gene variation
11. 2 new therapies show promise for cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Adventitious changes in cellular DNA can endanger the whole ... cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report ... the double helix. , The DNA in our cells ... in our bodies. The instructions for this are encoded ... in DNA, the bases adenine (A), cytosine (C), guanine ...
(Date:5/22/2013)... NEW YORK, May 22, 2013. Plastic additives known ... just about everywhere: They turn up in flooring, ... andaccording to the Centers for Disease Control and ... harmless, phthalates have come under increasing scrutiny. A ... phthalates (which can leech from packaging and mix ...
(Date:5/21/2013)... the body, stem cells in the blood often ... mature immune cells that can fight off illness. ... cell populations, potentially leading to the development of ... team of researchers led by biologists at the ... in mouse models, the molecule microRNA-146a (miR-146a) acts ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2
... Tufts University today announced the public launch of the ... The Institute is university-wide, global pharmaceutical ... portfolio of drug discovery and development partnerships. ... Tufts University School of Medicine and Tufts University,s Advancement ...
... FASEB MARC (Minority Access to Research Careers) Program ... American College of Sports Medicine (ACSM) Southeast Chapter Annual ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... it,s messy, smelly and typically problematic. Live bait is inconvenient ... more permanent lures, you run the risk of losing an ... of brightly colored plastic familiar from your father,s tackle box, ... Professor John Caprio and Mystic Tackleworks have changed all that ...
Cached Biology News:Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB 2Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB 3LSU biologist, chemical engineer partner with industry to develop best soft lure available 2LSU biologist, chemical engineer partner with industry to develop best soft lure available 3LSU biologist, chemical engineer partner with industry to develop best soft lure available 4
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... in Scotland, which boasts more than 380,000 visitors annually, ... powered by the Freedom® portable driver as part ... most advanced exhibitions of its kind. , “BodyWorks ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... America,Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... focused on,bringing the life saving potential of stem ... revenues for 2007 totaled $5.8,million, up 74 percent ... of an adjustment in how we recognized yearly ...
... Institute of Standards and Technology (NIST) have combined ... single microchip, a cryogenic sensor and a microrefrigerator. ... and faster precision analysis of materials such as ... upcoming issue of Applied Physics Letters,* the NIST ...
... Mr. Glynn has over 34 years of,combined financial, ... the life sciences industry for his role in the ... Glynn,retired from Invitrogen Corporation (Nasdaq: IVGN ) in ... several operating roles including CFO,President and COO and CEO. ...
Cached Biology Technology:Cord Blood America Reports $5.8 Million In Revenues In 2007, Up 74 Percent 2NIST micro sensor and micro fridge make cool pair 2eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Ether 30% concentration in ... Surfactant. Clear Solution. Recommended ... 1 mL of 30% ... to 400 mL of ...
Biology Products: